

Summary of COVID-19 therapeutics and related agreements

This table tracks various development, production, supply, funding, and intellectual property agreements for COVID-19 therapeutics. The information included in the table was sourced from publicly available information such as company websites and reputable news sources. Please note: the contents of this table are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of this table is to begin to identify agreements related to the COVID-19 response, however it should not be relied upon to provide a complete overview of the current landscape.

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<b>Dexamethasone, Glucocorticoid</b>	<b>RECOVERY (University of Oxford)</b> ClinicalTrials.gov Identifier: NCT04381936 (Phase 3) EU Clinical Trials Register Identifier: 2020-001113-21	<b>RECOVERY:</b> UK Research and Innovation/National Institute for Health Research (NIHR) NIHR Oxford Biomedical Research Centre (core funding) Wellcome (core funding) Gates Foundation (core funding) UK Department for International Development (core funding) Health Data Research UK (core funding) Medical Research Council Population Health Research Unit (core funding) NIHR Clinical Trials Unit Support (core funding)	<b>RECOVERY:</b> Grant Agreement between University of Oxford & UK Research and Innovation/National Institute for Health Research (NIHR)

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<p><b>Veklury/Remdesivir, nucleotide analog</b></p> <p><i>Gilead Sciences</i></p> <p>EUA granted by U.S. FDA</p>	<p><b>DisCoVeRy (INSERM)</b>            ClinicalTrials.gov Identifier: NCT04315948 (Recruiting)            EU Clinical Trials Register Identifier: 2020-000936-23</p> <p><b>SIMPLE (Gilead Sciences)</b>            ClinicalTrials.gov Identifiers: NCT04292730 &amp; NCT04292899 (Phase 3)</p> <p><b>CARAVAN (Gilead Sciences)</b>            ClinicalTrials.gov Identifier: NCT04431453 (Phase 2/3)</p> <p><b>ACCT (NIAID)</b>            ClinicalTrials.gov Identifier: NCT04280705 (Phase 3)</p> <p><b>Capital Medical University/ Chinese Academy of Medical Sciences/China-Japan Friendship Hospital</b>            ClinicalTrials.gov Identifiers: NCT04252664 &amp; NCT04257656 (Suspended/Terminated)</p> <p><b>U.S. Army Medical Research and Development Command</b>            ClinicalTrials.gov Identifier: NCT04302766 (expanded access)</p> <p><b>Gilead Sciences</b>            ClinicalTrials.gov Identifier: NCT04323761 (expanded access)</p> <p><b>FMTVDM (Camelot Foundation)</b></p>		<p>Collaboration between Gilead &amp; Feinstein Institutes</p> <p>Licensing Agreements between Gilead &amp; five Generics Manufacturers in India &amp; Pakistan</p>

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
	ClinicalTrials.gov Identifier: NCT04349410 (Phase 2/3)		
<b>REGN-COV2</b> , Antibody cocktail (REGN10933 + REGN10987) against the spike protein  <b>Regeneron Pharmaceuticals</b>	<b>Regeneron</b> ClinicalTrials.gov Identifiers: NCT04452318 (Phase 3), NCT04425629 (Phase 1/2), NCT04426695 (Phase 1/2)	BARDA	Collaboration between Regeneron & NIAID  Funding partnership between BARDA & Regeneron  Manufacture and supply agreement between BARDA & Regeneron
<b>Lopinavir-ritonavir (Kaletra)</b> , HIV protease inhibitor  <b>AbbVie</b> - AbbVie has stated that it will not defend its patent rights	<b>RECOVERY (University of Oxford)</b> ClinicalTrials.gov Identifier: NCT04381936 (Phase 2/3)  <b>Tonji Hospital</b> ClinicalTrials.gov Identifier: NCT04255017 (Phase 4)  <b>Asan Medical Center</b> ClinicalTrials.gov Identifier: NCT04307693 (Phase 2)  <b>Wuhan Jinyintan Hospital</b> Chinese Clinical Trials Registry Identifier: ChiCTR2000029308	<b>RECOVERY:</b> UK Research and Innovation/National Institute for Health Research (NIHR)  NIHR Oxford Biomedical Research Centre (core funding)  Wellcome (core funding)  Gates Foundation (core funding)  UK Department for International Development (core funding)  Health Data Research UK (core funding)  Medical Research Council Population Health Research Unit (core funding)	<b>RECOVERY:</b> Grant agreement between University of Oxford & UK Research and Innovation/National Institute for Health Research (NIHR)  <b>FLARE:</b> Funding partnership between UCL and LifeArc

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
	<b>FLARE (University College London)</b> ClinicalTrials.gov Identifier: NCT04499677 (Phase 2)	NIHR Clinical Trials Unit Support (core funding)	
<b>COVID-19 Convalescent Plasma</b>	<p><b>NYU Langone Health</b>            ClinicalTrials.gov Identifier: NCT04364737            (Phase 2)</p> <p><b>Brigham and Women's Hospital</b>            ClinicalTrials.gov Identifier: NCT04361253            (Phase 3)</p> <p><b>Cedars-Sinai Medical Center &amp; Johns Hopkins University</b>            ClinicalTrials.gov Identifier: NCT04353206            (Phase 1)</p> <p><b>Johns Hopkins University</b>            ClinicalTrials.gov Identifier: NCT04323800            (Phase 2)</p> <p><b>Johns Hopkins University</b>            ClinicalTrials.gov Identifier: NCT04377672            (Phase 1)</p> <p><b>Johns Hopkins University</b>            ClinicalTrials.gov Identifier: NCT04373460            (Phase 2)</p> <p><b>Baylor Research Institute</b>            ClinicalTrials.gov Identifier: NCT04333251            (Phase 1)</p> <p><b>Stanford University</b>            ClinicalTrials.gov Identifier: NCT04355767            (Phase 3)</p>		<p><b>NYU Langone Health:</b> Collaborations between NYU Langone Health, Albert Einstein College of Medicine &amp; Yale University</p> <p><b>Johns Hopkins (NCT04373460):</b> Collaborations between Johns Hopkins, State of Maryland, Bloomberg Foundation, U.S. Department of Defense &amp; NIAID</p> <p><b>Stanford University:</b> Collaboration between Stanford, National Heart, Lung, and Blood Institute (NHLBI) &amp; Strategies to Innovate EmergENcy Care Clinical Trials Network (SIREN)</p>

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
	<b>Stony Brook University</b> ClinicalTrials.gov Identifier: NCT04344535 (Phase 1/2)		
<b>Convalescent plasma and hyperimmune globulin</b>	<b>Grifols</b> (Pre-Clinical)	U.S. Department of Defense BARDA	Funding partnership between Grifols, U.S. Department of Defense & BARDA
<b>Leronlimab (PRO 140),</b> Humanized IgG4 monoclonal antibody  <i>CytoDyn</i>	<b>CytoDyn</b> ClinicalTrials.gov Identifiers: NCT04343651 (Phase 2), NCT04347239 (Phase 2b/3)		Collaboration agreement between CytoDyn & Mexican National Institutes of Health  Licensing & development letter of intent between CytoDyn & Longen China Group
<b>Antibodies</b>  <i>Centivax, Inc.</i>	Pre-clinical testing	Crowdfunding	Manufacturing partnership between Centivax & SwiftScale)
<b>VIR-2703 (ALN-COV)</b> siRNA candidate  <i>Vir Biotech &amp; Alnylam Pharmaceuticals</i>	Pre-clinical testing		Expansion of existing license & collaboration agreement between Vir & Alnylam
<b>Avigan/Favilavir/ Favipiravir (generic)/ Avifavir (generic),</b> Antiviral agent  <i>Fujifilm Toyama Chemical (markets Avigan in Japan)</i>	<b>Appili Therapeutics</b> ClinicalTrials.gov Identifier: NCT04499677 (Phase 2)  <b>Glenmark Pharmaceuticals</b> (Phase 3)  <b>Fujifilm Pharmaceuticals U.S.A., Inc.</b> ClinicalTrials.gov Identifier: NCT04358549 (Phase 3)	Donation of Avigan by Fujifilm Toyama/Government of Japan  <b>FLARE:</b> LifeArc  <b>PIONEER trial:</b> LifeArc	Supply and distribution partnership between Government of Japan and United Nations Office for Project Services  <b>Appili:</b> collaborations between Appili, Sinai Health, University of Toronto, Sunnybrook Health Sciences Centre & Unity Health Toronto  <b>FLARE:</b> funding partnership between University College London and LifeArc

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<b>Zhejiang Hisun Pharmaceutical (markets Favilavir in China)</b>	Clinical trials at hospitals in Wuhan & Shenzhen  <b>FLARE (University College London)</b> ClinicalTrials.gov Identifier: NCT04499677 (Phase 2)  <b>PIONEER (Chelsea and Westminster NHS Foundation Trust)</b> ClinicalTrials.gov Identifier: NCT04373733 (Phase 2)		<b>PIONEER:</b> Funding agreement between Imperial College London, Chelsea and Westminster Hospital NHS Foundation Trust, Royal Brompton Hospital & LifeArc
<b>VIR-7831 and VIR-7832, antibodies from recovered SARS patients</b>  <b>Vir Biotechnology, Inc.</b>	Pre-clinical testing		Collaboration agreement between Vir & GSK  Manufacturing agreement between Samsung & Vir  Development and manufacturing agreement between Vir & WuXi Biologics  Manufacturing letter of intent between Vir & Biogen Inc.
<b>Actemra/ Tocilizumab, Interleukin-6 (IL-6) receptor antagonist</b>  <b>Genentech</b>	<b>COVACTA (Roche)</b> ClinicalTrials.gov Identifier: NCT04320615 (Phase 3)  <b>CORIMUNO-19 (Hôpitaux de Paris)</b> ClinicalTrials.gov Identifier: NCT04331808 (Phase 2)  <b>Anhui Provincial Hospital</b> Chinese Clinical Trials Registry Identifier: ChiCTR2000029765 (Phase 4)  <b>TOCIVID-19 (National Cancer Institute, Naples)</b> ClinicalTrials.gov Identifier: NCT04317092 (Phase 2)	<b>COVACTA: BARDA</b>	Funding partnership between Genentech & BARDA  Supply agreement between Genentech & U.S. Department of Health and Human Services (commitment of 10,000 vials to the U.S. Strategic National Stockpile)

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
	<b>Università Politecnica delle Marche</b> ClinicalTrials.gov Identifier: NCT04315480 (Phase 2)		
<b>Jakafi/Jakavi (ruxolitinib),</b> kinase inhibitor  <i>Novartis (markets Jakavi outside the U.S.)</i>  <i>Incyte (markets Jakafi in the U.S.)</i>	<b>RUXCOVID-DEVENT (Incyte)</b> ClinicalTrials.gov Identifier: NCT04377620 (Phase 3)  <b>Incyte</b> ClinicalTrials.gov Identifier: NCT04377620 (expanded access program)  <b>RUXCOVID (Novartis/Incyte)</b> ClinicalTrials.gov Identifier: NCT04362137 (Phase 3)  <b>RAVEN (King's College London)</b>  <b>Tongji Hospital, Huazhong University of Science and Technology</b>	<b>RAVEN:</b> LifeArc, free of charge supply of Ruxolitinib by Novartis	<b>RAVEN:</b> Funding partnership between King's College London, Guy's and St Thomas' Hospital & LifeArc
<b>CT-P13 (infliximab), anti-tumour necrosis factor (TNF) therapy</b>  <i>Celltrion Healthcare UK</i>	<b>CATALYST (University of Birmingham)</b>		Partnership between the University of Birmingham, University Hospitals Birmingham and the Birmingham National Institute for Health Research Biomedical Research Centre, NIHR Oxford Biomedical Research Centre & University College London NIHR Biomedical Research Centre
<b>COVID-19 Human Immune Globulin (HIG), human plasma-based treatment</b>  Emergent BioSolutions	Pre-clinical testing	BARDA	Funding partnership between Emergent & BARDA

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<b>MultiStem bone marrow stem cells</b>  <i>Athersys</i>	<b>BREATHE (Kinevant Sciences GmbH)</b> ClinicalTrials.gov Identifier: NCT04351243 (Phase 2)  <b>MACOVIA (Athersys, Inc.)</b> ClinicalTrials.gov Identifier: NCT04367077 (Phase 2/3)		<b>BREATHE:</b> Clinical trial collaboration partnership between Kinevant & Roivant Sciences, Inc.  <b>MACOVIA:</b> Partnership between Athersys & University Hospitals  <b>MACOVIA:</b> CRO agreement between Athersys & Medpace
<b>VIR-2703 (also referred to as ALN-COV), RNAi therapeutic</b>  <i>Alnylam Pharmaceuticals</i>	Pre-Clinical		Expansion of existing development & licensing agreement between Alnylam Pharmaceuticals & Vir Biotechnology
<b>Hydroxychloroquine and chloroquine</b>	<b>RECOVERY (University of Oxford)</b> ClinicalTrials.gov Identifier: NCT04381936 (Phase 2/3)  <b>ORCHID (Massachusetts General Hospital)</b> ClinicalTrials.gov Identifier: NCT04381936 (Phase 3)  <b>A5395 (NIAID)</b> ClinicalTrials.gov Identifier: NCT04358068 (Phase 2b)  <b>Novartis</b> ClinicalTrials.gov Identifier: NCT04358081 (Phase 3)  <b>COVID-19 PEP (University of Washington)</b> ClinicalTrials.gov Identifier: NCT04328961 (Phase 2/3)  <b>CROWN CORONA (Washington University School of Medicine)</b>	<b>RECOVERY:</b> UK Research and Innovation/National Institute for Health Research (NIHR)  NIHR Oxford Biomedical Research Centre (core funding)  Wellcome (core funding)  Gates Foundation (core funding)  UK Department for International Development (core funding)  Health Data Research UK (core funding)  Medical Research Council Population Health Research Unit (core funding)  <b>A5395:</b> donation of medications for the study by Teva	<b>RECOVERY:</b> Grant agreement between University of Oxford & UK Research and Innovation/ NIHR  <b>ORCHID:</b> Clinical trial collaboration between Massachusetts General Hospital & National Heart, Lung, and Blood Institute  <b>A5395:</b> Clinical trial collaboration between NIAID & Teva  <b>COVID-19 PEP study</b> Clinical trial collaboration between University of Washington & Gates Foundation  <b>CROWN CORONA:</b> Clinical trial collaboration between Washington University & Gates Foundation  <b>HAHPS:</b> Clinical trial collaboration between Intermountain Health Care & University of Utah



Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
	<p>ClinicalTrials.gov Identifier: NCT04333732 (Phase 3)</p> <p><b>HAHPS (Intermountain Health Care, Inc.)</b> ClinicalTrials.gov Identifier: NCT04329832 (Phase 2)</p> <p><b>HyAzOUT (Intermountain Health Care, Inc.)</b> ClinicalTrials.gov Identifier: NCT04334382 (Phase 3)</p> <p><b>Rutgers</b> ClinicalTrials.gov Identifier: NCT04336332 (Phase 2)</p> <p><b>COPCOV (University of Oxford)</b> ClinicalTrials.gov Identifier: NCT04303507</p> <p><b>SOLIDARITY (Oslo University Hospital)</b> ClinicalTrials.gov Identifier: NCT04321616</p> <p><b>DisCoVeRy trial (INSERM)</b> ClinicalTrials.gov Identifier: NCT04315948 (Phase 3)</p> <p><b>PRINCIPLE (University of Oxford)</b> EU Clinical Trials Register Identifier: 2020-001209-22</p>		<p><b>HyAzOUT:</b> Clinical trial collaboration between Intermountain Health Care, University of Utah &amp; Utah Department of Health</p> <p><b>SOLIDARITY:</b> collaboration between multiple parties</p> <p><b>PRINCIPLE:</b> Funding agreement between University of Oxford and UK Research and Innovation/ NIHR</p>
<p><b>Dapagliflozin (Farxiga),</b> Oral sodium-glucose co-transporter 2 (SGLT2) inhibitor <i>Bristol-Myers Squibb</i></p>	<p><b>DARE-19 (Saint Luke's Health System)</b> ClinicalTrials.gov Identifier: NCT04350593 (Phase 3)</p>		<p>Clinical trial collaboration between Saint Luke's, AstraZeneca &amp; George Clinical Pty Ltd</p>

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<b>Acalabrutinib (Calquence)</b> , Kinase inhibitor <i>AstraZeneca</i>	<b>CALAVI/CALAVI US (AstraZeneca)</b> ClinicalTrials.gov Identifier: NCT04346199/NCT04380688 (Phase 2)  <b>AstraZeneca</b> ClinicalTrials.gov Identifier: NCT04497948 (Phase 1)  <b>ACCORD (University of Southampton)</b> EU Clinical Trials Register Identifier: 2020-001736-95		<b>AstraZeneca trials:</b> Clinical trial collaboration between AstraZeneca & Acerta Pharma B.V.  <b>ACCORD:</b> Clinical trial collaboration between University of Southampton, UK Research and Innovation/NIHR & IQVIA
<b>Ravulizumab (Ultomiris)</b> , Human monoclonal antibody <i>Alexion Pharmaceuticals</i>	<b>Alexion</b> ClinicalTrials.gov Identifier: NCT04369469 (Phase 3)		
<b>Ivermectin (Stromectol)</b> , Antihelmintic <i>Merck</i>	Pre-clinical (Kitasato Institute & Merck)		
<b>Sarilumab (Kevzara)</b> , IL-6 receptor antagonist <i>Sanofi &amp; Regeneron</i>	<b>Regeneron</b> ClinicalTrials.gov Identifier: NCT04315298 (Phase 2/3)	BARDA	Clinical trial collaboration between Sanofi, Regeneron & Feinstein Institutes  Funding Partnership between Regeneron & BARDA
<b>Canakinumab (Ilaris)</b> , Human monoclonal antibody <i>Novartis</i>	<b>Regeneron</b> ClinicalTrials.gov Identifier: NCT04362813 (Phase 3)		
<b>Famotidine (Pepcid)</b> , H2 blocker <i>Yamanouchi Pharmaceutical Co., J&amp;J, Merck</i>	<b>MATCH (Northwell Health)</b> ClinicalTrials.gov Identifier: NCT04370262 (Phase 3)		

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
MSTT1041A (anti-ST2) & UTTR1147A (IL-22-Fc) <i>Genentech</i>	COVASTIL ( <b>Genentech</b> ) ClinicalTrials.gov Identifier: NCT04386616 (Phase 2)	BARDA	Funding partnership between Genentech & BARDA
Mesenchymal Stem Cells (MSCs) <i>Novellus, Inc.</i>	Pre-clinical		In-license option agreement between Citius Pharma & Novellus
Danoprevir ( <b>Ganovo</b> ) hepatitis C virus NS3 protease inhibitor  & Ritonavir HIV protease inhibitor <i>Asclepis Pharma Inc.</i>	<b>The Ninth Hospital of Nanchang</b> ClinicalTrials.gov Identifier: NCT04291729 (Phase 4)  <b>The First Affiliated Hospital, Zhejiang University School of Medicine</b> ClinicalTrials.gov Identifier: ChiCTR2000029603		Clinical trial collaboration between Asclepis & Ninth Hospital of Nanchang
CYNK-001 allogeneic natural killer cell therapy <i>Celularity Incorporated</i>	CYNK001COVID ( <b>Celularity</b> ) ClinicalTrials.gov Identifier: NCT04291729 (Phase 1/2)		Amended collaborative licensing agreement between Celularity & Lung Biotechnology PBC  Clinical trial collaboration between Celularity, Lung Biotechnology & IDRI
TJM2 (TJ003234) anti-granulocyte-macrophage colony stimulating factor antibody <i>I-MAB Biopharma</i>			
EIDD-2801 oral ribonucleoside analog	<b>Ridgeback Biotherapeutics</b> ClinicalTrials.gov Identifier: NCT04392219 (Phase I)		License agreement between Emory & Ridgeback

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
<b>Drug Innovation Ventures at Emory (DRIVE)</b>			Collaboration agreement between Merck & Ridgeback
<b>Otilimab</b> , Monoclonal antibody <b>MorphoSys</b>	<b>OSCAR (GSK)</b> ClinicalTrials.gov Identifier: NCT04376684 (Phase 2)		
<b>LY-CoV555</b> , Monoclonal antibody <b>Eli Lilly &amp; AbCellera</b>	<b>Eli Lilly</b> ClinicalTrials.gov Identifier: NCT04411628 (Phase 1)	Canadian Government	Collaboration between Eli Lilly & AbCellera  Funding agreement between AbCellera & Government of Canada for development of antibodies & manufacturing
<b>INOpulse</b> , Nitric Oxide <b>Bellerophon Therapeutics, Inc.</b>	<b>Bellerophon Pulse Technologies</b> ClinicalTrials.gov Identifier: NCT04421508 (Phase 3)		
<b>Gimsilumab</b> , anti-granulocyte-macrophage colony stimulating factor monoclonal <b>Roivant Sciences</b>	<b>BREATHE (Kinevant Sciences GmbH)</b> ClinicalTrials.gov Identifier: NCT04351243 (Phase 2)  <b>Altasciences</b> (phase 1)		Clinical trial collaboration between AltaSciences & Roivant
<b>Lenzilumab</b> , Anti-human GM-CSF monoclonal antibody <b>Humanigen, Inc.</b>	<b>Humanigen</b> ClinicalTrials.gov Identifier: NCT04351152 (Phase 3)		CDMO agreement between Humanigen & Catalent  CRO agreement between Humanigen & CTI
<b>Mavrilimumab</b> , Monoclonal antibody <b>Kiniksa Pharmaceuticals</b>	<b>The Cleveland Clinic</b> ClinicalTrials.gov Identifier: NCT04399980 (Phase 2)  <b>Kiniksa Pharmaceuticals</b> ClinicalTrials.gov Identifier: NCT04447469 (Phase 2/3)		Clinical trial collaboration between Cleveland Clinic & Kiniksa

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
CD24Fc, Recombinant fusion protein <i>Oncolmmune, Inc.</i>	<b>Oncolmmune</b> ClinicalTrials.gov Identifier: NCT04399980 (Phase 3)		
JS016, Monoclonal antibody <i>Eli Lilly &amp; Junshi Biosciences</i>	<b>Shanghai Junshi Bioscience Co., Ltd.</b> ClinicalTrials.gov Identifier: NCT04441918 (Phase 1)		Collaboration agreement between Eli Lilly & Junshi Biosciences
SAB-185 Polyclonal hyperimmune globulin (H-IG) <i>SAb Biotherapeutics</i>	Pre-Clinical	BARDA	Funding partnership between SAB & BARDA
Allogeneic T-cell therapies <i>AlloVir</i>	Pre-Clinical		Expansion of research collaboration between AlloVir & Baylor College of Medicine
Antibodies from recovered COVID-19 patients <i>Amgen &amp; Adaptive Biotechnologies</i>	Pre-Clinical		MoU between Amgen & Adaptive
Monoclonal antibody combination <i>Vanderbilt University Medical Center</i>	Pre-Clinical	DARPA & BARDA	Licensing agreement between AstraZeneca & Vanderbilt  Licensing agreement between IDBiologics & Vanderbilt  Funding partnership between AstraZeneca & BARDA/DARPA
Super-antibody or antibody cocktail to	Pre-Clinical		

Therapeutic ( <i>developer</i> )	Related clinical trials	Funders	Related Agreements/partnerships/collaborations
target potential mutations of SARS-CoV-2 <i>Celltrion</i>			
Antibodies from recovered COVID-19 patients <i>Celltrion</i>	Pre-Clinical		Pre-clinical testing collaboration between Celltrion & Chungbuk National University College of Medicine
Inhaled mRNA <i>Neurimmune AG &amp; Ethris GmbH</i>	Pre-Clinical		Collaboration agreement between Neurimmune & Ethris
Scanning antiviral compounds previously in development <i>Pfizer</i>	Pre-Clinical		
Polyclonal hyperimmune globulin (H-IG) <i>CoVlg-19 Plasma Alliance</i>	Pre-Clinical		Alliance between Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, & Sanquin